Novel combination therapy shown to be effective in ovarian cancer

(The Wistar Institute) Wistar researchers have found combining PARP inhibitors, recently approved for the treatment of BRCA-mutant ovarian cancer, with another small molecule inhibitor was effective to treat ovarian cancers without BRCA1 and BRCA2 gene mutations.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news